Cellectar Biosciences (CLRB) said Wednesday the US Food and Drug Administration has granted breakthrough therapy designation to its experimental cancer drug, iopofosine I 131, for the treatment of relapsed or refractory Waldenstrom macroglobulinemia, a rare and currently incurable form of lymphoma.
The company said the designation was based on results from a phase 2 trial, where the drug achieved an 83.6% overall response rate and a 58.2% major response rate, significantly exceeding its 20% target.
Cellectar said it also submitted a data package to the European Medicines Agency to determine whether it can pursue conditional marketing authorization in the EU, adding that a recommendation on whether to proceed with a full application is expected by late July 2025.
Shares of the company were up more than 43% in Wednesday's premarket activity.
Price: 0.40, Change: +0.12, Percent Change: +43.62
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。